Silexion Therapeutics enters ATM equity facility for up to $13.17M via H.C. Wainwright

Silexion Therapeutics Corp

At-the-market offering agreement with H.C. Wainwright to sell up to $13.17M of ordinary shares.
Wainwright to receive 3% commission on gross proceeds; sales may occur via Nasdaq Capital Market.
Offering terminates upon sale of all shares or earlier termination by either party.
Company not obligated to sell any shares; sales subject to effectiveness of registration statement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.